TLSI Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 9.18%, SMA50 -6.2%, SMA200 3.5%). The stock’s 14-day RSI is 53.84 (neutral), while the ATR of 0.4 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -32.33% below its high and over 57.31% above its low. Average 10-day trading volume of 924.77 thousand shares is significantly above the 3-month average of 297.69 thousand, indicating heightened recent market interest.

TriSalus Life Sciences, Inc. generated EPS of -$2.02 over the past year. Five-year average earnings growth is -175.42%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $7.00. The high target offers 349.44% upside. The low target suggests 162.17% downside. The mean target is $10.33. This offers 286.89% upside. TriSalus Life Sciences, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 12, 2026, missed forecasts by 106.25%. The prior quarter beat by -7.69%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 27, 2025.

TriSalus Life Sciences, Inc. has 49.87 million shares outstanding. The public float is 39.49 million shares, elevated short interest at 1.25% of float. This equals 457.06 thousand shares. The short ratio is 4.11 days. Institutional investors hold 30.48% of the float. Insiders own 43.32%. Frankenius Equity AB holds 6.23 million shares, Szela Mary T has 752.99 thousand shares and Patience David has 268.66 thousand shares. Over the past six months, insider transactions show net selling. They sold 33.68 thousand shares across 14 transactions.

TriSalus Life Sciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$8.06. This means the shares are trading below this model’s fair value.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) closed at $2.67 USD, losing -$1.89 (-41.45%) from the previous close of $4.56. The stock is currently mid-range between its 52-week high and low $2.22 and $7.95. With a market capitalization of about $101.22 million, TriSalus Life Sciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.56). Key stats such as the average daily volume over the past year has been around 180.47 thousand shares, trading with heavier-than-usual volume. Headquartered in Westminster, CO, TriSalus Life Sciences, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Mary T. Szela, the company employs approximately 110 people and listed since February 08, 2021. TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors.

TriSalus Life Sciences, Inc. trades at a P/E ratio of -5.16, slightly below the S&P 500 average, with a price-to-sales ratio of 2.31 and a price-to-book ratio of 11.01 reflecting a rich premium to book value. The P/FCF stands at -5.11, also above market averages. Compared to sector medians, TriSalus Life Sciences, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that TriSalus Life Sciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 71.16%, with price expected at $4.57 by May 26, 2026, within a range of $4.42 to $4.72 3-Month Outlook: Projected fall of -62.55%, reaching $1.00 by August 10, 2026, with a range of $0.75 to $1.15. 1-Year Outlook: Projected gain of 83.9%, with price at $4.91 by May 12, 2027, within a range of $0.00 to $7.74.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) shares are down -24.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows TriSalus Life Sciences, Inc. trading at a premium to the broader market with a P/E of -5.16. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.67, suggesting 299.63% upside. Our AI forecast model points to short-term strength (71.16% over two weeks), a medium-term fall (-62.55% over three months), and a longer-term gain (83.9% over one year), with expected trading ranges indicating moderate volatility.